FDY-5301

DRUG3 trials

Sponsors

Faraday Pharmaceuticals, Inc.

Conditions

Acute Myocardial InfarctionICU Acquired WeaknessPercutaneous Coronary RevascularizationSTEMI

Phase 2

A Study of Acute Myocardial Infarction Using FDY-5301

CompletedNCT03470441

Faraday Pharmaceuticals, Inc.Acute Myocardial Infarction, STEMI

Start: 2017-10-27End: 2019-01-03Updated: 2026-01-16

Evaluation of FDY-5301 in Major Trauma Patients in ICU

TerminatedNCT04430283

Faraday Pharmaceuticals, Inc.ICU Acquired Weakness

Start: 2021-09-20End: 2022-03-04Updated: 2023-06-13

Phase 3

Evaluation in STEMI Patients Using FDY-5301

CompletedNCT04837001

Faraday Pharmaceuticals, Inc.Acute Myocardial Infarction, Percutaneous Coronary Revascularization, STEMI

Start: 2022-05-02End: 2025-09-03Updated: 2025-09-12

Related Papers

A Randomized, double-blind, dose ranging clinical trial of intravenous FDY-5301 in acute STEMI patients undergoing primary PCI.

2021-11-1213 citations